These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. IL-12 improves the anti-HCC efficacy of dendritic cells loaded with exosomes from overexpressing Rab27a tumor cells. Li J; Lin W; Huang T; Chen M; Lin Q Exp Cell Res; 2024 Jun; 439(1):114073. PubMed ID: 38704079 [TBL] [Abstract][Full Text] [Related]
4. Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo. Chen Z; You L; Wang L; Huang X; Liu H; Wei JY; Zhu L; Qian W J Exp Clin Cancer Res; 2018 Aug; 37(1):190. PubMed ID: 30103789 [TBL] [Abstract][Full Text] [Related]
5. Alarmin-painted exosomes elicit persistent antitumor immunity in large established tumors in mice. Zuo B; Qi H; Lu Z; Chen L; Sun B; Yang R; Zhang Y; Liu Z; Gao X; You A; Wu L; Jing R; Zhou Q; Yin H Nat Commun; 2020 Apr; 11(1):1790. PubMed ID: 32286296 [TBL] [Abstract][Full Text] [Related]
6. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells. Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200 [TBL] [Abstract][Full Text] [Related]
7. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395 [TBL] [Abstract][Full Text] [Related]
8. Suppression of hepatocellular carcinoma by transplantation of ex-vivo immune-modulated NKT lymphocytes. Margalit M; Shibolet O; Klein A; Elinav E; Alper R; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y Int J Cancer; 2005 Jun; 115(3):443-9. PubMed ID: 15688366 [TBL] [Abstract][Full Text] [Related]
9. Antigen-specific T cell response from dendritic cell vaccination using side population cell-associated antigens targets hepatocellular carcinoma. Li X; Zhang Z; Lin G; Gao Y; Yan Z; Yin H; Sun B; Wang F; Zhang H; Chen H; Cao D Tumour Biol; 2016 Aug; 37(8):11267-78. PubMed ID: 26951511 [TBL] [Abstract][Full Text] [Related]
10. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo. Gonzalez-Carmona MA; Lukacs-Kornek V; Timmerman A; Shabani S; Kornek M; Vogt A; Yildiz Y; Sievers E; Schmidt-Wolf IG; Caselmann WH; Sauerbruch T; Schmitz V Hepatology; 2008 Jul; 48(1):157-68. PubMed ID: 18537185 [TBL] [Abstract][Full Text] [Related]
11. Anti-tumor efficacy of a hepatocellular carcinoma vaccine based on dendritic cells combined with tumor-derived autophagosomes in murine models. Su S; Zhou H; Xue M; Liu JY; Ding L; Cao M; Zhou ZX; Hu HM; Wang LX Asian Pac J Cancer Prev; 2013; 14(5):3109-16. PubMed ID: 23803088 [TBL] [Abstract][Full Text] [Related]
12. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403 [TBL] [Abstract][Full Text] [Related]
13. Autologous Tumor Cell Lysate-Loaded Dendritic Cell Vaccine Inhibited Tumor Progression in an Orthotopic Murine Model for Hepatocellular Carcinoma. Wang Q; Luan W; Warren L; Kadri H; Kim KW; Goz V; Blank S; Isabel Fiel M; Hiotis SP Ann Surg Oncol; 2016 Dec; 23(Suppl 5):574-582. PubMed ID: 26786094 [TBL] [Abstract][Full Text] [Related]
14. The role of extracellular vesicles in mediating progression, metastasis and potential treatment of hepatocellular carcinoma. Yang N; Li S; Li G; Zhang S; Tang X; Ni S; Jian X; Xu C; Zhu J; Lu M Oncotarget; 2017 Jan; 8(2):3683-3695. PubMed ID: 27713136 [TBL] [Abstract][Full Text] [Related]
15. Exosomes: small vesicles with big roles in hepatocellular carcinoma. Wu Z; Zeng Q; Cao K; Sun Y Oncotarget; 2016 Sep; 7(37):60687-60697. PubMed ID: 27463001 [TBL] [Abstract][Full Text] [Related]
16. Suppression of hepatocellular carcinoma growth via oral immune regulation towards tumor-associated antigens is associated with increased NKT and CD8+ lymphocytes. Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y Oncology; 2004; 66(4):323-30. PubMed ID: 15218301 [TBL] [Abstract][Full Text] [Related]
17. Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells. Sun JC; Pan K; Chen MS; Wang QJ; Wang H; Ma HQ; Li YQ; Liang XT; Li JJ; Zhao JJ; Chen YB; Pang XH; Liu WL; Cao Y; Guan XY; Lian QZ; Xia JC Cancer Biol Ther; 2010 Aug; 10(4):368-75. PubMed ID: 20581468 [TBL] [Abstract][Full Text] [Related]
18. Serum-derived exosomes function as tumor antigens in patients with advanced hepatocellular carcinoma. Shi S; Wang L; Wang C; Xu J; Niu Z Mol Immunol; 2021 Jun; 134():210-217. PubMed ID: 33819783 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapy based on dendritic cells pulsed with CTPFoxM1 fusion protein protects against the development of hepatocellular carcinoma. Su H; Li B; Zheng L; Wang H; Zhang L Oncotarget; 2016 Jul; 7(30):48401-48411. PubMed ID: 27351282 [TBL] [Abstract][Full Text] [Related]
20. Potential therapeutic value of dendritic cells loaded with NY‑ESO‑1 protein for the immunotherapy of advanced hepatocellular carcinoma. Chen Y; Huang A; Gao M; Yan Y; Zhang W Int J Mol Med; 2013 Dec; 32(6):1366-72. PubMed ID: 24085111 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]